Catalyst Brief

← Calendar

Readoutin 165d

Merck Sharp & Dohme LLC — Pembrolizumab

Phase 3 primary completion: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012).

Date
May 2027
Type
Readout
Indication
Lung Neoplasms

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Merck Sharp & Dohme LLC

  1. May2027
  2. Jan2027
  3. Jan2027
  4. Nov2026